跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
查看斯高帕斯 (Scopus) 概要
許 瀚水
教授
急重症醫學研究所
電話
(02)2875-7546
電子郵件
hshsu2
ym.edu
tw
h-index
h10-index
h5-index
7537
引文
48
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1675
引文
23
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
634
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1995 …
2026
每年研究成果
概覽
指紋
網路
研究成果
(200)
類似的個人檔案
(6)
指紋
查看啟用 Han-Shui Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Esophageal Squamous Cell Carcinoma
100%
Lung Cancer
72%
Non-small Cell Lung Cancer (NSCLC)
43%
Overall Survival
43%
Prognostic Factors
38%
Overexpression
29%
Esophagectomy
29%
Taiwan
29%
Poor Prognosis
27%
Thymoma
26%
Surgical Resection
26%
Esophageal Cancer
26%
Neoadjuvant Chemoradiotherapy (nCRT)
26%
Tumor
26%
Lung Adenocarcinoma
24%
Myasthenia Gravis
23%
Protein Expression
23%
Disease-free Survival
22%
Catenin
21%
Tumor Size
20%
Lung Cancer Patients
20%
Stage I Lung Cancer
20%
Surgical Outcomes
19%
Cancer Stem Cells
19%
Promoter Methylation
18%
Recurrence-free Survival
17%
Hazard Ratio
16%
In Cancer
16%
Cancer Stem-like
16%
Murine Double Minute 2 (MDM2)
15%
5-year Survival
15%
Deregulation
15%
Resection
14%
Ground-glass Opacity
14%
Thymectomy
14%
Methylation
14%
Lymphadenectomy
14%
Bleomycin-induced Pulmonary Fibrosis
14%
Tumor Metastasis
13%
Acute Respiratory Distress Syndrome
13%
DNA Methyltransferase 1 (DNMT1)
13%
Metastasis
13%
Lung
13%
Extended Thymectomy
12%
Surgical Intensive Care Unit
12%
Taipei
12%
CD133
12%
Tumor Suppressor Gene
12%
Adenocarcinoma
12%
Early-stage Lung Cancer
12%
Medicine and Dentistry
Esophageal Squamous Cell Carcinoma
79%
Neoplasm
63%
Surgery
58%
Lung Cancer
56%
Esophagectomy
46%
Non Small Cell Lung Cancer
44%
Overall Survival
44%
Prognostic Factor
40%
Esophageal Cancer
33%
Chemoradiotherapy
31%
Esophagus
27%
Survival Rate
26%
Thymus Cancer
25%
Metastatic Carcinoma
25%
Thymectomy
24%
Squamous Cell Carcinoma
22%
Pneumonectomy
20%
Retroperitoneal Lymph Node Dissection
20%
Intensive Care Unit
20%
Computer Assisted Tomography
20%
Disease Free Survival
19%
Myasthenia gravis
19%
Diseases
19%
Recurrent Disease
17%
Hazard Ratio
17%
Lung Adenocarcinoma
17%
Protein Expression
15%
Lung
15%
Retrospective Study
15%
Ground Glass Opacity
14%
Thoracic Wall
14%
Video-Assisted Thoracoscopic Surgery
14%
Promoter Region
13%
Lung Nodule
13%
Recurrence Free Survival
12%
Extubation
11%
Survival Analysis
11%
Methylation
10%
Lymph Node
10%
Malignant Neoplasm
10%
Small-Cell Carcinoma
10%
Cancer
10%
Acute Respiratory Distress Syndrome
10%
Cancer Cell
9%
Radiation Therapy
8%
Tumor Recurrence
8%
Proportional Hazards Model
8%
Artificial Respiration
8%
Thymic Carcinoma
8%
Lymph Node Metastasis
8%
